dr. tolaney on remaining questions with cdk4/6 inhibitors in hr /her2- breast cancer
Published 4 years ago • 131 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
1:59
dr. tolaney on selecting patients for cdk4/6 inhibitors in breast cancer
-
1:41
dr. tolaney on activity with abemaciclib in patients with hr /her2– breast cancer
-
1:12
remaining questions on the use of frontline cdk4/6 inhibitors endocrine therapy
-
2:02
dr. tolaney on sequencing questions in breast cancer
-
1:39
dr. tolaney on novel approaches in treating her2-positive breast cancer
-
1:20
dr tolaney on ongoing clinical trials in early-stage her2 breast cancer
-
1:39
dr. tolaney on sequencing strategies in metastatic her2 breast cancer
-
14:40
cdk4/6i in hr sabcs 2022 highlights - oncbrothers (rohit and rahul gosain) with dr. sara tolaney
-
1:32
dr tolaney on data with checkpoint inhibitor combinations in metastatic tnbc
-
7:37
dr. tolaney highlights new breast cancer combination therapies
-
1:20
dr tolaney on the potential role for biomarkers in early-stage her2 breast cancer
-
1:55
dr. tolaney on abemaciclib plus pembrolizumab for hr , her2- breast cancer
-
1:38
dr. tolaney on cns recurrence in her2 breast cancer
-
1:10
dr. tolaney discusses unmet needs in er breast cancer
-
1:39
dr tolaney on standard frontline treatment approaches in her2 breast cancer
-
1:32
dr. tolaney on the evolution of treatment in her2 breast cancer
-
2:06
dr. tolaney on deescalating therapy in stage i her2 breast cancer
-
1:08
dr. tolaney discusses the role of chemotherapy in her2 breast cancer